Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009
about
Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic reviewRapid Molecular Detection of Multidrug-Resistant Tuberculosis by PCR-Nucleic Acid Lateral Flow ImmunoassayWhat are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis.Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance.Mycobacterium tuberculosis Whole Genome Sequences From Southern India Suggest Novel Resistance Mechanisms and the Need for Region-Specific Diagnostics.Isoniazid-resistant tuberculosis: a cause for concern?Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13.Target product profile of a molecular drug-susceptibility test for use in microscopy centers.Drug resistance patterns of Mycobacterium tuberculosis complex and associated factors among retreatment cases around Jimma, Southwest Ethiopia.Global and Regional Burden of Isoniazid-Resistant TuberculosisGenetic variation in Mycobacterium tuberculosis isolates from a London outbreak associated with isoniazid resistanceMulticenter Evaluation of Anyplex Plus MTB/NTM MDR-TB Assay for Rapid Detection of Mycobacterium tuberculosis Complex and Multidrug-Resistant Isolates in Pulmonary and Extrapulmonary SpecimensIsoniazid-resistant tuberculosis in children: a systematic reviewCommunity-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis.Rapid Detection of Mycobacterium tuberculosis Strains Resistant to Isoniazid and/or Rifampicin: Standardization of Multiplex Polymerase Chain Reaction Analysis.Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa.Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study.Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.Donor-derived tuberculosis (TB): isoniazid-resistant TB transmitted from a lung transplant donor with inadequately treated latent infection.Treatment outcomes for isoniazid-resistant tuberculosis under program conditions in British Columbia, Canada.Do we need to detect isoniazid resistance in addition to rifampicin resistance in diagnostic tests for tuberculosis?Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis.Isoniazid-Monoresistance and Rate of Culture Conversion among Confirmed Tuberculosis Patients in the State of Georgia, 2009 - 2014.Fluoroquinolone Preventive Therapy after Exposure to Multidrug-Resistant Tuberculosis? Hopes and Fears.Isoniazid Monoresistance: A Precursor to Multidrug-Resistant Tuberculosis?Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care.Using routinely collected laboratory data to identify high rifampicin-resistant tuberculosis burden communities in the Western Cape Province, South Africa: A retrospective spatiotemporal analysisA systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis
P2860
Q28544877-9A9B4008-9879-4055-AD93-8A25E9B0D7AAQ28547835-8969F140-6715-4641-BBAB-33ACBE13644DQ30249635-A39DD68B-1C4B-4F13-8C19-41230629FA38Q33595994-A578278E-DBF9-426B-994B-8BD04E59E02AQ33696037-BD693550-6A7B-422E-A572-7B85EEB26A99Q33820505-29E7B87E-E957-4CE7-8805-7B48057F0BCDQ33902627-93D73803-4A07-432F-918F-A2E403CE58D1Q35588123-4C48BC1A-22EA-4BC7-8E95-0A7EBEDDE193Q35681236-87EC6475-68FB-4332-8E86-E1A93AF25E9BQ35795714-A5F4A501-64FB-43ED-A5A6-65AB07C36933Q36105274-28EA3A54-831F-4A5D-A46C-2F910A6B9253Q36434491-3B903B79-DCA6-43FB-849C-E60D09F10FB4Q37004599-C9595E37-402C-4D3D-807E-5340F6B38FBFQ37021617-EAB4A685-F399-4C1F-87EF-30B025AB1794Q38950600-5E673A6E-A345-4A33-A656-D033AA8B939AQ40210228-1368F81D-7521-43DA-A9E1-B0AD9DE3FB67Q40401590-2AEE928B-7F26-45CE-8B8C-A2BABB97D316Q40542672-07193E7A-CF2C-4EB1-A1B2-6BE673A30CE8Q40599406-2B32FD55-CF55-4BDE-B874-528D0BC10087Q41611075-3983CDDB-2B7E-451F-A0B2-DC01EA386054Q41849725-048F9D0F-CC19-4413-BCF6-18AD1B46B4E1Q42211847-ED9BCEFA-FD3F-457B-AF0B-C83522A26B1CQ50048481-2A68BE73-2997-4D6E-8D17-BCF22DCDA8EDQ51612576-C604C2E8-86B7-4BDA-884F-82471E5C58FCQ52679975-94A812FD-F727-49FB-860A-F76645C55DD5Q52707803-EF4F4550-E0A1-47C2-A6DE-05FAB6588404Q58731377-01566258-695E-4AD1-98F6-6F81F35D0AB7Q58794430-72DEECC0-C555-4785-8A26-F4AB03D165EA
P2860
Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009
@ast
Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009
@en
type
label
Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009
@ast
Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009
@en
prefLabel
Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009
@ast
Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009
@en
P2093
P2860
P1433
P1476
Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009
@en
P2093
Helen E Jenkins
Matteo Zignol
P2860
P304
P356
10.1371/JOURNAL.PONE.0022927
P407
P577
2011-07-29T00:00:00Z